Fusion Molecules Between the STAT5b Inhibitor Stafib-2-CR and a Cereblon Ligand

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Selective inhibition of Signal Transducer and Activator of Transcription 5b (STAT5b) is difficult due to its similarity to STAT5a.
• Catechol bisphosphates, particularly Stafib-2-CR, have emerged as potent selective STAT5b inhibitors.

Purpose of the Study:

• To design and synthesize fusion molecules for STAT5b-selective proteolysis-targeting chimeras (PROTACs).
• To evaluate the STAT5b inhibitory activity and potential for cell-permeable prodrug development of these fusion molecules.

Main Methods:

• Synthesis of fusion molecules linking Stafib-2-CR with a cereblon E3 ligase ligand.
• Assessment of STAT5b inhibitory activity using competitive fluorescence polarization assays.
• Exploration of prodrug strategies for enhanced cell permeability.

Main Results:

• The synthesized fusion molecules maintained STAT5b inhibitory activity.
• The most potent compound demonstrated activity comparable to Stafib-2-CR.
• Challenges were encountered in converting the lead fusion molecule into a cell-permeable prodrug.

Conclusions:

• The linker and exit vector choices are suitable for STAT5b binding in PROTAC design.
• Combining prodrug strategies with PROTAC technology presents significant hurdles.
• Further research is needed to overcome challenges in developing cell-permeable STAT5b-targeting PROTACs.